United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - chloramphenicol sodium succinate (unii: 872109hx6b) (chloramphenicol - unii:66974fr9q1) - chloramphenicol 1 g in 10 ml - in accord with the concepts in the   warning box   and this   indications and usage   section, chloramphenicol must be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated.  however, chloramphenicol may be chosen to initiate antibiotic therapy on the clinical impression that one of the conditions below is believed to be present; in vitro sensitivity tests should be performed concurrently so that the drug may be discontinued as soon as possible if less potentially dangerous agents are indicated by such tests.  the decision to continue use of chloramphenicol rather than another antibiotic when both are suggested by in vitro studies to be effective against a specific pathogen should be based upon severity of the infection, susceptibility of the pathogen to the various antimicrobial drugs, efficacy of the various drugs in the infection, and the important additional conce

United States - English - NLM (National Library of Medicine)

bimeda, inc. - chloramphenicol (unii: 66974fr9q1) (chloramphenicol - unii:66974fr9q1) - chloramphenicol 250 mg - indications : chloramphenicol tablets are recommended for oral treatment of the following conditions in dogs: - bacterial pulmonary infections caused by susceptible microorganisms such as: staphylococcus aureus , streptococcus pyogenes and brucella bronchiseptica . - infections of the urinary tract caused by susceptible microorganisms such as: escherichia coli , proteus vulgaris , corynebacterium renale , streptococcus spp., and hemolytic staphylococcus . - enteritis caused by susceptible microorganisms such as: e. coli , proteus spp., salmonella spp., and pseudomonas spp. - infections associated with canine distemper caused by susceptible microorganisms such as: b. bronchiseptica , e. coli , p. aeruginosa , proteus spp., shigella spp. and neisseria catarrhalis . additional adjunctive therapy should be used when indicated. most susceptible infectious disease organisms will respond to chloramphenicol therapy in three to five days when the recommended dosage regimen is followed. if no response to chloram

United States - English - NLM (National Library of Medicine)

darmerica, llc - chloramphenicol (unii: 66974fr9q1) (chloramphenicol - unii:66974fr9q1) -

United States - English - NLM (National Library of Medicine)

kalchem international - chloramphenicol (unii: 66974fr9q1) (chloramphenicol - unii:66974fr9q1) -

United States - English - NLM (National Library of Medicine)

darmerica, llc - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol - unii:66974fr9q1) -

United States - English - NLM (National Library of Medicine)

attix pharmaceuticals - chloramphenicol (unii: 66974fr9q1) (chloramphenicol - unii:66974fr9q1) - chloramphenicol 25 kg in 25 kg

United States - English - NLM (National Library of Medicine)

parke-davis - chloramphenicol (unii: 66974fr9q1) (chloramphenicol - unii:66974fr9q1) - ointment - chloramphenicol should be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. bacteriological studies should be performed to determine the causative organisms and their sensitivity to chloramphenicol (see boxed warning). chloromycetin ophthalmic ointment, 1% (chloramphenicol ophthalmic ointment, usp) is indicated for the treatment of surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. the particular antiinfective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus streptococcus , including streptococcus pneumoniae escherichia coli haemophilus influenzae klebsiella/enterobacter species moraxella lucunata     (morax-axenfeld bacillus) neisseria species this product does not provide adequate coverage against: pseudomonas aeruginosa serratia marcescens this product is contraindicated in persons sensitive to any of its components.

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - chloramphenicol (unii: 66974fr9q1) (chloramphenicol - unii:66974fr9q1) - chloramphenicol 24.75 kg in 25 kg

United States - English - NLM (National Library of Medicine)

american pharmaceutical ingredients llc - chloramphenicol (unii: 66974fr9q1) (chloramphenicol - unii:66974fr9q1) -

United States - English - NLM (National Library of Medicine)

ax pharmaceutical corp - chloramphenicol palmitate (unii: 43vu4207nw) (chloramphenicol - unii:66974fr9q1) - chloramphenicol palmitate .99 kg in 1 kg